Galectin Therapeutics GALT Cash Flow Statement (2010-2026)

NASDAQ GALT
$3.43 -0.06 (-1.86%)
At close: Oct 20, 2026 · 4:00 PM EDT
Reported Financials

Galectin Therapeutics Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jun 2026

Galectin Therapeutics reported cash from operations of -$2.40M and free cash flow of -$2.40M for the quarter ended Jun 2026, up 63.6% year over year. This cash flow statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-8.52M-7.22M-9.93M-9.61M-8.60M-10.63M-11.53M-9.11M-10.43M-10.00M-11.49M-12.37M-11.22M-11.97M-9.63M-7.52M-8.18M-5.50M-5.05M-9.11M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
Share-based CompensationStock Comp.
0.59M0.65M0.86M0.65M0.68M0.68M0.66M0.52M0.59M0.41M0.60M0.74M0.52M0.59M0.47M0.50M0.50M0.20M0.78M0.96M
Gains from Equity InvestmentsGains Equity
Other non-cash itemsOther Non-Cash
0.19M-0.30M-0.14M-0.19M0.35M-0.14M0.95M-0.34M0.69M-0.14M1.08M0.14M1.05M-1.71M0.37M1.45M2.42M0.46M-0.83M3.31M
Change in Working Capital
Change in Accured ExpensesChange Accured Exp.
2.35M0.67M0.86M1.28M-1.25M3.35M-1.37M-1.66M0.62M5.08M-3.29M5.16M1.20M1.37M1.40M-4.64M7.72M1.76M1.83M1.85M
Change in Other Operating AssetsOther Assets Change
-0.34M0.86M-0.16M-0.29M-0.32M0.67M-0.18M-0.28M-0.25M0.80M-0.15M-0.22M-0.08M0.53M-0.22M-0.21M-0.47M0.48M-0.14M-0.07M
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
0.34M-0.86M0.16M0.29M0.32M-0.67M0.18M0.28M0.25M-0.80M0.15M0.22M0.08M-0.53M0.22M0.21M0.47M-0.48M0.14M0.07M
Cash from OperationsCash from Ops.
-5.00M-6.95M-8.04M-7.43M-8.35M-7.24M-10.79M-9.83M-7.64M-4.74M-12.11M-8.33M-8.56M-12.80M-7.70M-6.60M-3.53M-6.07M-3.90M-2.41M
Investing Activities
Capital ExpendituresCapex
Change in Property, Plant and EquipmentChange in PP&E
Purchase of InvestmentsInvestments Purchased
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
10.00M10.00M
Non-Current Debt
10.00M10.00M
Short-Term Debt issuancesST Debt Issuance
10.00M10.00M10.00M10.00M10.00M10.00M10.00M11.00M10.00M0.26M-0.26M
Current Debt
10.00M10.00M10.00M10.00M10.00M10.00M10.00M11.00M10.00M0.26M-0.26M
Net Debt Issuances and RepaymentsNet Debt Issuance
10.00M10.00M10.00M10.00M10.00M10.00M10.00M10.00M10.00M11.00M10.00M0.26M-0.26M
Change in Capital Stock
Common Stock IssuedStock Issued
0.00M0.85M1.30M2.24M
Net Shares Issued and RepurchasedNet Shares Issued
0.00M0.85M1.30M2.24M
Net Equity Issued and RepurchasedNet Equity Issued
0.00M0.85M1.30M2.24M
Dividend Payments
Dividends Paid - PreferredDiv. Paid (Pref.)
Dividends Paid - Common and PrefferdDiv Paid (Total)
Other financing activitiesOther financing
-0.16M-0.16M-0.30M-0.30M0.30M-0.09M-0.09M
Cash from Financing ActivitiesCash from Financing
10.00M10.00M10.00M10.00M10.00M10.03M10.00M10.00M10.38M10.00M0.85M12.94M1.30M12.24M0.26M1.60M
Additional items
Change in Cash
5.00M3.05M-8.04M-7.43M-8.35M2.76M-0.79M0.17M2.40M5.30M-2.11M2.04M1.46M-11.94M-7.69M6.34M-2.25M6.20M-3.61M-0.84M
Ending Cash Balance
36.60M39.65M31.61M24.18M15.83M18.59M18.00M17.97M20.36M25.66M23.56M25.60M27.06M15.12M7.43M13.77M11.53M17.72M14.11M13.27M
Free Cash FlowFCF
-5.00M-6.95M-8.04M-7.43M-8.35M-7.24M-10.79M-9.83M-7.64M-4.74M-12.11M-8.33M-8.56M-12.80M-7.70M-6.60M-3.53M-6.07M-3.90M-2.41M
Net Cash FlowNCF
5.00M3.05M-8.04M-7.43M-8.35M2.76M-0.79M0.17M2.40M5.26M-2.11M2.04M1.44M-11.95M-7.70M6.34M-2.24M6.17M-3.64M-0.81M

Galectin Therapeutics Cash Flow Statement API

Pull Galectin Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GALT&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY